• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > About

What they say about us

Home > About

What they say about us

Loading...

In the DRC, the treatment of NTDs over the past 17 years has been supported by DNDi in a broad partnership with the government and other donors. We urge governments, public and private funders around the world to continue to support research and development efforts to meet the need for access to treatment for patients.

Dr Naomie Awaca Uvon

Physician-Director of the National Programme for Fight against Neglected Tropical Diseases with Preventive Chemotherapy (PNLMTN-CTP), Democratic Republic of the Congo

Naomie Awaca Uvon

DNDi's innovative approach and collaborative spirit have revolutionized the treatment of neglected diseases, bringing hope and health to millions of patients. Thanks to our collaboration, the Mycetoma Research Centre is conducting the first-ever double-blind, randomized clinical trial for an effective mycetoma treatment.

Prof. Ahmed Hassan Fahal

Professor of Surgery & Director, The Mycetoma Research Centre, Sudan

Prof. Ahmed Hassan Fahal

People affected by neglected diseases must have access to treatments. DNDi helps to ensure that new medical products are available and affordable for all.

Christian Frutiger

Ambassador, Assistant Director General, Head of Global Cooperation, Swiss Agency for Development and Cooperation

Over the past 20 years, DNDi has made a significant contribution to manufacturing drugs that are affordable in low- and middle-income countries, empowering governments in their disease elimination programmes.

Nirmal Ganguly

Former Director General, The Indian Council of Medical Research (ICMR)

Nirmal Ganguly

Treatment for children living with HIV is a humanitarian effort. At Cipla, we are proud to have partnered with DNDi in this important mission.

Dr Yusuf Hamied

CEO & Chair of Cipla Pharmaceuticals, CIPLA, India

Dr Yusuf Hamied Mumbai 2020

With the necessary will and commitment, we know hepatitis C can be eliminated. Our local and global partnerships, notably with DNDi, are ensuring we have the medical tools and strategies in place to succeed.

Dr Noor Hisham Abdullah

Former Director-General of Health, Malaysia Ministry of Health

We hope our research partnership with DNDi can confirm earlier positive results of a new treatment combination that could help improve the lives of people with cutaneous leishmaniasis in Latin America.

Marcia Hueb

Researcher and principle investigator of the Phase III CL study, Mato Grosso Federal University, Brazil

Dr Marcia Hueb

DNDi’s innovative and collaborative approach to pharmaceutical research and development has made a difference in the lives of so many. We are proud to have been a founding partner of DNDi and to stand by you in the fight for equitable access to life-saving medicines.

Dr Farhat Mantoo

General Director, MSF South Asia

Farhat Mantoo

Because PKDL is not fatal it has largely been ignored by public health efforts, but our research with DNDi shows that early treatment of PKDL patients will be a critical element of any leishmaniasis public health and elimination strategy.

Dr Dinesh Mondal

Acting Senior Director, Laboratory Sciences and Services Division, icddr,b, Bangladesh

Partnerships are essential to the success of clinical research advances in the treatment of NTDs. The fexinidazole treatment for sleeping sickness is a perfect example of how collaboration can fuel the discovery of drugs that are effective, easy to use and with few side effects.

Prof. Jean-Jacques Muyembe

General Director Biomedical Research Institute (INRB), Democratic Republic of the Congo

Prof. Jean-Jacques Muyembe

DNDi's dynamic approach to finding solutions, with their unique ability to coordinate partners like an orchestra conductor, has resulted in bringing together different stakeholders in hepatitis C and dengue. Their innovative approach and collaborative spirit have not only brought hope to millions worldwide but have also set a new standard for neglected disease treatment.

Dr Shahnaz Murad

Former Deputy Director-General of Health (Research & Technical Support), Ministry of Health, Malaysia

Murad Shahnaz

The Ministry of Health, Malaysia is proud to be a founding partner of DNDi. Our partnership puts patients first. We have shown that together, we can improve the lives of millions.

Dr Zaliha Mustafa

Former Minister of Health, Ministry of Health, Malaysia

Dr Zaliha

Fexinidazole is a true game-changer for sleeping sickness. If acoziborole, a single-dose treatment, is shown to be safe and effective, we’re hopeful it would provide national programmes an even better tool to help achieve global elimination goals.

Katey Owen

Director of Neglected Tropical Diseases, Bill & Melinda Gates Foundation

We are deeply grateful and proud to have been a part of the team that brought a new, affordable treatment for hepatitis C to the world. We remain committed to collaborating with DNDi and partners to ensure that innovative, affordable treatments reach all those in need.

Dr Muhammad Radzi Abu Hassan

Director-General of Health, Ministry of Health, Malaysia

Dr Muhammad Radzi Abu Hassan

The value of pharmaceutical research and development cannot be overstated, especially in sub-Saharan Africa. DNDi is fostering collaboration and investment in R&D that is addressing the pressing need for access to safe, effective, and affordable treatments. Together we are working towards creating a brighter future for our communities.

Prof. Elijah Songok

 Acting Director-General, Kenyan Medical Research Institute (KEMRI)

Our invaluable partnership with DNDi has been a source of immense pride for us. Your dedication and commitment over the past two decades have made a remarkable difference to people living with neglected diseases.

Prof. Shyam Sundar

Programme Director, Kala Azar Research Centre (KAMRC), India

Shyam Sundar

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License